Navidea Biopharmaceuticals (NAVB) Stock Price Down 21.1%

Navidea Biopharmaceuticals Inc (NYSEAMERICAN:NAVB) dropped 21.1% on Thursday . The company traded as low as $0.13 and last traded at $0.15. Approximately 2,901,617 shares changed hands during trading, an increase of 670% from the average daily volume of 376,728 shares. The stock had previously closed at $0.19.

Navidea Biopharmaceuticals (NYSEAMERICAN:NAVB) last posted its quarterly earnings data on Wednesday, November 7th. The biopharmaceutical company reported ($0.02) EPS for the quarter. The firm had revenue of $0.23 million during the quarter.

COPYRIGHT VIOLATION NOTICE: This piece of content was published by Sports Perspectives and is the property of of Sports Perspectives. If you are reading this piece of content on another site, it was illegally copied and republished in violation of U.S. & international copyright and trademark laws. The legal version of this piece of content can be accessed at https://sportsperspectives.com/2018/12/07/navidea-biopharmaceuticals-navb-stock-price-down-21-1.html.

Navidea Biopharmaceuticals Company Profile (NYSEAMERICAN:NAVB)

Navidea Biopharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of precision immunodiagnostic agents and immunotherapeutics. The company operates in two segments, Diagnostic Substances and Therapeutic Development Programs. The company develops Manocept platform to target the CD206 mannose receptor expressed on activated macrophages; and NAV4694, a fluorine-18 labeled positron emission tomography imaging agent for use as an aid in the imaging and evaluation of patients with signs or symptoms of Alzheimers disease and mild cognitive impairment.

Read More: What is the Dow Jones Industrial Average (DJIA)?

Receive News & Ratings for Navidea Biopharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Navidea Biopharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply